Herb Cross

CIK: 0001230721

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

JSPR

Jasper Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

JSPR
Jasper Therapeutics, Inc.
Jan 2, 2026
Award(A)
Stock Option (right to buy)
Direct
90K shares-
JSPR
Jasper Therapeutics, Inc.
Jun 4, 2025
Award(A)
Stock Option (right to buy)
Direct
90K shares-
JSPR
Jasper Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option (right to buy)
Direct
50K shares-

		Type	Shares	Price		Ownership
Jan 2, 2026	JSPR Jasper Therapeutics, Inc.	Award(A) Stock Option (right to buy)	90,000	-	-	Direct
Jun 4, 2025	JSPR Jasper Therapeutics, Inc.	Award(A) Stock Option (right to buy)	90,000	-	-	Direct
Feb 13, 2025	JSPR Jasper Therapeutics, Inc.	Award(A) Stock Option (right to buy)	50,000	-	-	Direct

1-3 of 3 transactions

About CROSS HERB

CROSS HERB (SEC CIK 0001230721) files insider reports with the SEC as Chief Financial Officer of Jasper Therapeutics, Inc. (JSPR).

Signal8 holds 3 ownership filings by CROSS HERB, all Form 4s, filed between Feb 18, 2025 and Jan 5, 2026. Those filings report 3 transactions, from Feb 13, 2025 to Jan 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on CROSS HERB's filings is in REDWOOD CITY, CA.

Recent filings by CROSS HERB

Jan 2, 2026: Grant or award of JSPR derivative securities (Form 4, code A).
Jun 4, 2025: Grant or award of JSPR derivative securities (Form 4, code A).
Feb 13, 2025: Grant or award of JSPR derivative securities (Form 4, code A).

Other insiders filing for Jasper Therapeutics, Inc. (JSPR)

WIGGANS THOMAS G, Director
Lucas Svetlana, Director
Crutcher Patrick J, Director
EMSTER KURT VON, Director
Shizuru Judith Anne, Director
Keenan Greg, Chief Medical Officer

How to read Form 4 transaction codes